0.95
price down icon2.08%   -0.0202
pre-market  Pre-mercato:  .96   0.01   +1.05%
loading
Precedente Chiudi:
$0.9702
Aprire:
$0.9873
Volume 24 ore:
90,196
Relative Volume:
0.71
Capitalizzazione di mercato:
$20.89M
Reddito:
-
Utile/perdita netta:
$-22.29M
Rapporto P/E:
-0.8051
EPS:
-1.18
Flusso di cassa netto:
$-17.12M
1 W Prestazione:
-12.84%
1M Prestazione:
-20.83%
6M Prestazione:
-40.99%
1 anno Prestazione:
-76.25%
Intervallo 1D:
Value
$0.92
$1.03
Intervallo di 1 settimana:
Value
$0.92
$1.11
Portata 52W:
Value
$0.8101
$4.59

Enlivex Therapeutics Ltd Stock (ENLV) Company Profile

Name
Nome
Enlivex Therapeutics Ltd
Name
Telefono
-
Name
Indirizzo
-
Name
Dipendente
49
Name
Cinguettio
@EnlivexT
Name
Prossima data di guadagno
2024-09-09
Name
Ultimi documenti SEC
Name
ENLV's Discussions on Twitter

Confronta ENLV con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
ENLV
Enlivex Therapeutics Ltd
0.95 20.89M 0 -22.29M -17.12M -1.18
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.74 124.48B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
617.00 67.45B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
567.09 34.59B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
255.76 33.10B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
271.04 29.15B 3.81B -644.79M -669.77M -6.24

Enlivex Therapeutics Ltd Stock (ENLV) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2021-03-02 Reiterato H.C. Wainwright Buy

Enlivex Therapeutics Ltd Borsa (ENLV) Ultime notizie

pulisher
Mar 31, 2025

Enlivex Therapeutics Releases 2024 Financial Statements - TipRanks

Mar 31, 2025
pulisher
Mar 28, 2025

Enlivex Therapeutics (ENLV) to Release Quarterly Earnings on Friday - Defense World

Mar 28, 2025
pulisher
Mar 27, 2025

HC Wainwright Has Negative Estimate for ENLV FY2025 Earnings - Defense World

Mar 27, 2025
pulisher
Mar 26, 2025

HC Wainwright Forecasts Strong Price Appreciation for Enlivex Therapeutics (NASDAQ:ENLV) Stock - The AM Reporter

Mar 26, 2025
pulisher
Mar 25, 2025

Enlivex Therapeutics (NASDAQ:ENLV) Given New $7.00 Price Target at HC Wainwright - Defense World

Mar 25, 2025
pulisher
Mar 24, 2025

Enlivex stock price target raised to $7 at H.C. Wainwright By Investing.com - Investing.com South Africa

Mar 24, 2025
pulisher
Mar 24, 2025

Enlivex stock price target raised to $7 at H.C. Wainwright - Investing.com India

Mar 24, 2025
pulisher
Mar 17, 2025

Enlivex Secures Chinese Patent Allowance for Osteoarthritis Treatment - TipRanks

Mar 17, 2025
pulisher
Mar 17, 2025

Enlivex Receives Notice of Allowance for Chinese Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis - The Manila Times

Mar 17, 2025
pulisher
Mar 17, 2025

Enlivex Therapeutics Secures Patent Allowance in China for Allocetra™ as Treatment for Osteoarthritis - Nasdaq

Mar 17, 2025
pulisher
Mar 17, 2025

Breakthrough: Enlivex's Arthritis Drug Cuts Pain by 47%, Secures Major China Patent Win - StockTitan

Mar 17, 2025
pulisher
Mar 06, 2025

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Short Interest Update - Defense World

Mar 06, 2025
pulisher
Mar 05, 2025

IOBT To Report Melanoma Trial Data In Q3, NPCE Eyes 15-20% Revenue Growth For 2025, DXR On Watch - RTTNews

Mar 05, 2025
pulisher
Mar 05, 2025

Enlivex Therapeutics Announces Investor Webinar to Discuss Positive Interim Data from Phase I/II Allocetra™ Trial in Knee Osteoarthritis - The Manila Times

Mar 05, 2025
pulisher
Mar 04, 2025

Enlivex Reports Promising Interim Results in Osteoarthritis Trial - TipRanks

Mar 04, 2025
pulisher
Mar 04, 2025

Enlivex Therapeutics Announces Investor Webinar To Discuss Positive Interim Data From Phase I/Ii Allocetra(TM) Trial In Knee Osteoarthritis - Marketscreener.com

Mar 04, 2025
pulisher
Mar 04, 2025

Enlivex Therapeutics Ltd. Hosts Investor Webinar to Discuss Positive Interim Data from Allocetra™ Osteoarthritis Trial - Nasdaq

Mar 04, 2025
pulisher
Mar 04, 2025

Can Enlivex's Allocetra Transform Osteoarthritis Treatment? 47% Pain Reduction Reported - StockTitan

Mar 04, 2025
pulisher
Mar 04, 2025

Enlivex Therapeutics (NASDAQ:ENLV) Given Buy Rating at D. Boral Capital - Defense World

Mar 04, 2025
pulisher
Mar 03, 2025

Enlivex Announces Positive Interim Data From Early Stage Trial For Osteoarthritis Treatment - Nasdaq

Mar 03, 2025
pulisher
Mar 03, 2025

Enlivex Reports Promising Interim Results in Knee Osteoarthritis Trial - TipRanks

Mar 03, 2025
pulisher
Mar 03, 2025

Enlivex Announces Positive Interim DataStatistically Significant 47.0% Durable and Persistent Pain Reduction At Six Months, in Patients with Moderate to Severe Knee Osteoarthritis - The Manila Times

Mar 03, 2025
pulisher
Mar 03, 2025

Enlivex Therapeutics Reports Positive Interim Results in Phase I/II Trial of Allocetra™ for Knee Osteoarthritis - Nasdaq

Mar 03, 2025
pulisher
Mar 03, 2025

Can Enlivex's Osteoarthritis Treatment Disrupt a Multi-Billion Dollar Market? 6-Month Data Impresses - StockTitan

Mar 03, 2025
pulisher
Mar 01, 2025

We're Keeping An Eye On Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Rate - Simply Wall St

Mar 01, 2025
pulisher
Feb 19, 2025

Enlivex Advances Immunotherapy with Japanese Patent for Osteoarthritis Treatment - PUNE.NEWS

Feb 19, 2025
pulisher
Feb 18, 2025

Enlivex Therapeutics (NASDAQ:ENLV) Hails Positive Trial Results for Allocetra Treatment of Knee Osteoarthritis - Markets Insider

Feb 18, 2025
pulisher
Feb 18, 2025

Enlivex Therapeutics Starts Phase II Allocetra Trail to Treat Knee Osteoarthritis - Markets Insider

Feb 18, 2025
pulisher
Feb 18, 2025

Enlivex Wins Key Patent in Japan for Osteoarthritis Treatment - Markets Insider

Feb 18, 2025
pulisher
Feb 18, 2025

Enlivex Therapeutics Completes Initial Dosing in Phase I Psoriatic Arthritis Trial - Markets Insider

Feb 18, 2025
pulisher
Feb 18, 2025

Enlivex Issues Urgent Statement on Fraudulent News Dissemination - The Manila Times

Feb 18, 2025
pulisher
Feb 18, 2025

Enlivex Therapeutics Denies False Report of Trading Suspension and Reaffirms Business Operations - Nasdaq

Feb 18, 2025
pulisher
Feb 12, 2025

CollPlant Biotechnologies Provides a Corporate Update - Quantisnow

Feb 12, 2025
pulisher
Feb 11, 2025

Tryptamine Therapeutics Appoints New Auditor Amid Global Expansion - TipRanks

Feb 11, 2025
pulisher
Feb 11, 2025

RedChip Announces Webinar to Teach Investors How to Use RedChat, a Revolutionary AI Chatbot for Small-Cap Stock Analysis - Yahoo Finance

Feb 11, 2025
pulisher
Feb 10, 2025

Enlivex Therapeutics’ (ENLV) “Buy” Rating Reiterated at D. Boral Capital - Defense World

Feb 10, 2025
pulisher
Feb 06, 2025

Enlivex Therapeutics (NASDAQ:ENLV) Stock Price Up 1.9% – Time to Buy? - Defense World

Feb 06, 2025
pulisher
Jan 30, 2025

Sepsis Market Forecasted to Surge in Coming Years, 2024-2034 - openPR

Jan 30, 2025
pulisher
Jan 25, 2025

Enlivex Receives Regulatory Authorization From Israel’s Health Ministry For The Initiation Of Phase 1/2 Trial Evaluating Allocetra In Patients With Knee Osteoarthritis - ACCESS Newswire

Jan 25, 2025
pulisher
Jan 24, 2025

Enlivex Therapeutics and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - ACCESS Newswire

Jan 24, 2025
pulisher
Jan 19, 2025

Join Enlivex Therapeutics' Exclusive Live Investor Webinar and Q&A Session on December 3 - ACCESS Newswire

Jan 19, 2025
pulisher
Jan 14, 2025

Head-To-Head Analysis: Bright Minds Biosciences (NASDAQ:DRUG) versus Enlivex Therapeutics (NASDAQ:ENLV) - Defense World

Jan 14, 2025
pulisher
Jan 10, 2025

Enlivex CEO to Showcase Breakthrough Allocetra Cell Therapy on Bloomberg TV Special Feature - StockTitan

Jan 10, 2025
pulisher
Jan 07, 2025

Hoth’s phase IIa derma data in cancer patients propels its stock - BioWorld Online

Jan 07, 2025
pulisher
Jan 03, 2025

Enlivex Therapeutics (NASDAQ:ENLV) Stock Price Up 6% – Still a Buy? - Defense World

Jan 03, 2025
pulisher
Dec 12, 2024

Enlivex gains Israeli regulatory approval to commence TMJ osteoarthritis trial - Yahoo Finance

Dec 12, 2024
pulisher
Dec 11, 2024

Enlivex Receives Regulatory Authorization for the Initiation of A Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis - Marketscreener.com

Dec 11, 2024
pulisher
Dec 11, 2024

Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis - The Manila Times

Dec 11, 2024
pulisher
Dec 05, 2024

Enlivex Announces Positive Interim Efficacy Data from Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis - The Manila Times

Dec 05, 2024
pulisher
Dec 04, 2024

Trump's crypto advocacy steers businesses away from traditional treasury assets - Yahoo Canada Finance

Dec 04, 2024
pulisher
Dec 03, 2024

Enlivex's Allocetra Trial Shows 50% Pain Reduction in Knee Osteoarthritis Study - StockTitan

Dec 03, 2024

Enlivex Therapeutics Ltd Azioni (ENLV) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$67.94
price down icon 3.89%
$72.00
price down icon 5.62%
$31.17
price up icon 0.13%
$18.80
price down icon 2.54%
$90.29
price down icon 0.85%
biotechnology ONC
$271.04
price down icon 0.42%
Capitalizzazione:     |  Volume (24 ore):